GlobeNewswire by notified

Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

  • Continued commercial success of Cresemba and Zevtera in 2022 generated revenue contributions of approx. CHF 122 million, exceeding guidance by more than 17%
  • Significant proceeds from oncology transactions
  • Following pre-NDA (New Drug Application) meeting held with FDA in Q4 2022 for ceftobiprole (Zevtera), NDA submission for three indications planned within two to three months
  • Building a balanced R&D portfolio of antibacterial and antifungal drug candidates to support sustainable long-term growth in line with strategic refocus

Ad hoc announcement pursuant to Art. 53 LR

Basel/Allschwil, Switzerland, January 11, 2023

Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the unaudited preliminary revenues for the financial year 2022 and provided an update on the progress made with its commercial brands Cresemba® (isavuconazole) and Zevtera® (ceftobiprole), as well as in advancing its R&D portfolio in 2022.

Revenue contributions from the antifungal Cresemba and the antibiotic Zevtera are expected to amount to approximately CHF 122 million (full-year 2022 guidance: CHF 98 million – 104 million). Total revenue, which includes BARDA reimbursements1, proceeds from the oncology transactions and other revenue contributions in addition to the Cresemba and Zevtera contributions, is expected to amount to approximately CHF 148 million (full-year 2022 guidance: CHF 116 million – 122 million).

David Veitch, Chief Executive Officer, commented: “We achieved significant milestones in 2022 and will continue to focus on delivering on our strategy to drive value creation going forwards. This is supported by the continued commercial success, especially of Cresemba and, subject to receiving a marketing approval in the U.S, the anticipated increasing revenue contributions from Zevtera. We are also planning to in-license further preclinical and clinical assets in 2023 and beyond. Our goal is to maintain a balanced portfolio of innovative drug candidates for the treatment of severe bacterial and fungal infections to support the long-term growth of Basilea, beyond Cresemba and Zevtera, and in so doing execute on our strategic goal of becoming a leading anti-infectives company.”

The strong global commercial performance of Cresemba triggered a number of separate sales milestone payments to Basilea from its partners, related to Cresemba in-market sales; in the United States, Asia Pacific & China, Canada and the Nordics. By year-end 2022, Cresemba was approved in 73 countries and marketed in 63 countries, including the United States, most EU member states, China and additional countries inside and outside of Europe. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between October 2021 and September 2022 amounted to USD 363 million, a 19 percent growth year-on-year.2

Anti-infectives key highlights 2022


  • The intravenous and oral formulations of Cresemba were launched in China for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis, marking the entry into one of the most important markets for novel antifungals.
  • Patient recruitment was completed for the pediatric program. The completion of the pediatric program is a requirement for gaining an additional two years of marketing exclusivity in Europe and six months in the United States.
  • In December, Basilea’s partner Asahi Kasei Pharma received the marketing approval for Cresemba in Japan for the treatment of adult patients with aspergillosis, mucormycosis, and cryptococcosis.


  • In June, Basilea announced positive topline results for the phase 3 ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcus aureus (SAB).3 The ERADICATE study complements the TARGET phase 3 study in acute bacterial skin and skin structure infections (ABSSSI), which achieved positive results in 2019.4
  • In July, Zevtera received the marketing authorization in Brazil.

Dr. Marc Engelhardt, Chief Medical Officer, said: “In Q4 2022 we had a pre-NDA meeting with the U.S. Food and Drug Administration, which allowed us to finalize our regulatory strategy for ceftobiprole in the U.S. We will be seeking approval not only for Staphylococcus aureus bacteremia and acute bacterial skin and skin structure infections but also for community-acquired bacterial pneumonia. We aim to submit the corresponding New Drug Application within the next two to three months. While Staphylococcus aureus bacteremia is the indication of highest unmet medical need, we believe that a broader range of indications would further support the utility of ceftobiprole in a clinical practice setting.”

Preclinical programs

  • The work on an in-licensed DXR inhibitor program against multi drug-resistant Gram-negative bacteria progressed and Basilea expects to reach the next preclinical decision point in 2023.
  • Progress on advancing earlier internal programs continues.
  • Basilea has completed the profiling of a lead compound from a recently in-licensed preclinical program of broad-spectrum antifungals with a new mode of action. The candidate did not meet Basilea’s stringent criteria for progressing into the development stage and the company decided to return the program to the licensor.

Dr. Laurenz Kellenberger, Chief Scientific Officer, commented: “We made good progress advancing our pipeline with promising programs, from both internal and external innovation. Our competencies and know-how in research and development of anti-infectives, combined with a data-driven approach and decision making process allows us to quickly identify and then focus on the most promising candidates for further development and for in-licensing.”

Oncology transactions successfully completed in 2022

In February 2022, Basilea announced the strategic decision to focus exclusively on anti-infectives going forwards and to exit oncology by the end of 2022. By November 2022, Basilea had entered into three separate transactions with innovative oncology companies. These transactions related to novel preclinical stage inhibitors of PARG and CLK as well as BAL0891, a potential first-in-class mitotic checkpoint inhibitor. They were structured to provide upfront and near-term milestone payments, while also ensuring that Basilea maintains an ongoing participation in the long-term value creation potential of these promising programs.

On the oncology assets which were not transacted, Basilea decided to transfer the rights for the FGFR inhibitor derazantinib back to Merck & Co. For the tumor checkpoint controller lisavanbulin, Basilea concluded the study program last year, following a decision not to expand glioblastoma patient cohorts, retaining the option to explore partnering opportunities in the future. Basilea will not incur material costs related to any oncology activities in 2023.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have several preclinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit


This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Phone +41 61 606 1102

This ad hoc announcement can be downloaded from


  1. Basilea’s ceftobiprole phase 3 program is funded in part (up to USD 136.4 million, which is approximately 70% of the total potential program costs) with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C.
  2. IQVIA Analytics Link, September 2022. In-market sales reported as moving annual total (MAT) in U.S. dollar.
  3. ERADICATE study: identifier NCT03138733
    K. Hamed, M. Engelhardt, M. E. Jones et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial. Future Microbiology. 2020 (1), 35-48
  4. TARGET study: identifier NCT03137173
    J. S. Overcash, C. Kim, R. Keech R et al. Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET). Clinical Infectious Diseases 2021 (73), e1507-e1517


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Nikkiso Clean Energy & Industrial Gases Group Announces Expansion of Service for Middle East and Northern Africa30.1.2023 23:49:26 CET | Press release

TEMECULA, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Nikkiso Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is proud to announce yet another expansion of their manufacturing and service capabilities for the Middle East and Northern Africa markets. With this expansion, they will be providing pump and turboexpander aftermarket repairs of their full line, including J.C. Carter pumps. Their new state-of-the-art service center will allow repairs to be made locally rather than the need to ship elsewhere. The new facility, based in the Sharjah Free Zone, was established to provide expanded support for the Middle East and Northern Africa markets. They have added field service support, and shop technicians specifically trained to support Marine, J.C. Carter, Nikkiso Cryogenic Pumps (ACD and Nikkiso Cryo) and Turboexpanders. In addition to in-shop and on-site repairs, they will provide aftermarket service. “With this facility, we will b

Constellation Brands Prices Offering of Senior Notes30.1.2023 22:40:18 CET | Press release

VICTOR, N.Y., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that it priced the public offering of $500.0 million aggregate principal amount of 5.000% Senior Notes due 2026 (the “notes”) for a public offering price of 99.829% of the principal amount of the notes. The notes will be senior obligations that rank equally with all of Constellation’s other senior unsecured indebtedness. Closing of the offering is expected to occur on February 2, 2023. Constellation intends to use the net proceeds from the offering for general corporate purposes, including the repayment of a portion of its indebtedness outstanding under the delayed draw three-year term loan facility of its term loan credit agreement, dated as of August 9, 2022, as amended on October 18, 2022. BofA Securities, Inc., Goldman Sachs & Co. LLC, and J.P. Morgan Securities LLC are acting as the joint book-running managers of the offering. The notes are be

Nokia Corporation: Repurchase of own shares on 30.01.202330.1.2023 20:00:00 CET | Press release

Nokia Corporation Stock Exchange Release 30 January 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 30.01.2023 Espoo, Finland – On 30 January 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL279,9364.37CEUX20,9634.38AQEU7,9574.36TQEX6,3444.39Total315,2004.37 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023

Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group30.1.2023 18:00:00 CET | Press release

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022. Negma has requested conversion of two (2) convertible bonds issued on 3 January 2023, corresponding to SEK 50,000 of the convertible loan amounting to a total of SEK 13,700,000, into 20,325 shares. Upon registration at the Swedish Companies Registration Office, Mendus’ total share capital will amount to SEK 9,971,046.20 and the total number of shares and votes will amount to 199,420,924. The conversion price per share is SEK 2.46, equivalent to 92% of the second lowest closing volume weighted average share price (VWAP) of the 10 consecutive trading days preceding the issuance of conversion request by Negma. F

Mendus AB: Mendus tillkännager begäran från Negma Group om konvertering av konvertibla skuldebrev30.1.2023 18:00:00 CET | Pressemelding

Mendus AB (“Mendus” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på immunterapier mot tumöråterfall, tillkännager idag att Negma Group (”Negma”) genom meddelande till Mendus har begärt konvertering av konvertibla skuldebrev som utfärdats till Negma i enlighet med det finansieringsavtal som Mendus tillkännagivit genom pressmeddelanden den 26 augusti och 26 oktober 2022. Negma har begärt konvertering av två (2) konvertibla skuldebrev som emitterades den 3 januari 2023, motsvarande 50 000 kronor av det konvertibla lånet som uppgår till totalt 13 700 000 kronor, till 20 325 aktier. Efter registrering hos Bolagsverket kommer Mendus totala aktiekapital att uppgå till 9 971 046,20 kronor och det totala antalet aktier och röster kommer att uppgå till 199 420 924. Konverteringspriset per aktie är 2,46 kronor, motsvarande 92% av det näst lägsta dagliga volymvägda genomsnittliga aktiekursen (VWAP) under de 10 på varandra följande handelsdagarna före konverteringsbegäran från Negma. För ytte